Skip to main content

Table 3 Ongoing phase III immunotherapy trials in mCRPC

From: The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma

Trial National clinical trial identifier Status*
PSA-TRICOM +/- GM-CSF NCT01322490 Ongoing, Expected completion date June 2017
Tasquinimod NCT01234311 Completed, Reported in 2016 [61]
Ipilimumab in chemo-naïve mCRPC NCT01057810 Completed, Reported in 2016 [38]
  1. * As determined by ClinicalTrials.gov accessed October 31, 2016